ALLO moved below its 50-day moving average on November 06, 2023 date and that indicates a change from an upward trend to a downward trend. In of 36 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on November 29, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLO as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ALLO broke above its upper Bollinger Band on November 03, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALLO entered a downward trend on December 06, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where ALLO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ALLO just turned positive on December 06, 2023. Looking at past instances where ALLO's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.745) is normal, around the industry mean (20.710). P/E Ratio (0.000) is within average values for comparable stocks, (137.900). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. ALLO's P/S Ratio (2000.000) is slightly higher than the industry average of (330.425).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of allogeneic chimeric antigen receptor therapy
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
TBWAX | 16.44 | 0.03 | +0.18% |
Thornburg Better World International A | |||
SPRAX | 21.04 | -0.01 | -0.05% |
PGIM Quant Solutions Mid-Cap Val A | |||
AXVNX | 17.15 | -0.03 | -0.16% |
Acclivity Small Cap Value N | |||
MFRKX | 54.20 | -0.20 | -0.37% |
MFS Research R6 | |||
ACFOX | 45.25 | -0.22 | -0.48% |
American Century Focused Dynamic Gr Inv |
A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with NTLA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then NTLA could also see price increases.
Ticker / NAME | Correlation To ALLO | 1D Price Change % | ||
---|---|---|---|---|
ALLO | 100% | +1.59% | ||
NTLA - ALLO | 57% Loosely correlated | -0.17% | ||
BEAM - ALLO | 55% Loosely correlated | +1.49% | ||
MDGL - ALLO | 54% Loosely correlated | +0.54% | ||
EDIT - ALLO | 54% Loosely correlated | +1.18% | ||
SANA - ALLO | 53% Loosely correlated | -4.12% | ||
More |
Ticker / NAME | Correlation To ALLO | 1D Price Change % |
---|---|---|
ALLO | 100% | +1.59% |
drugs (undefined stocks) | 51% Loosely correlated | +1.33% |
biotechnology (undefined stocks) | 45% Loosely correlated | +1.71% |
therapy (undefined stocks) | 44% Loosely correlated | +3.84% |